Soleno Therapeutics Inc (NASDAQ: SLNO) on Friday, soared 7.78% from the previous trading day, before settling in for the closing price of $50.80. Within the past 52 weeks, SLNO’s price has moved between $21.30 and $56.81.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -1.94%. With a float of $25.93 million, this company’s outstanding shares have now reached $31.68 million.
Let’s determine the extent of company efficiency that accounts for 42 employees. In terms of profitability, gross margin is 41.09%, operating margin of -1982.56%, and the pretax margin is -1898.11%.
Soleno Therapeutics Inc (SLNO) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Soleno Therapeutics Inc is 33.29%, while institutional ownership is 80.54%. The most recent insider transaction that took place on Oct 07 ’24, was worth 125,204,132. Before that another transaction happened on Oct 01 ’24, when Company’s SEE REMARKS sold 3,108 for $49.43, making the entire transaction worth $153,627. This insider now owns 81,465 shares in total.
Soleno Therapeutics Inc (SLNO) Recent Fiscal highlights
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.95 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.58) by -0.37. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.64 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.94% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to 24.34% growth over the previous five years of trading.
Soleno Therapeutics Inc (NASDAQ: SLNO) Trading Performance Indicators
Soleno Therapeutics Inc (SLNO) is currently performing well based on its current performance indicators. A quick ratio of 29.24 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.43, a number that is poised to hit -0.60 in the next quarter and is forecasted to reach -2.03 in one year’s time.
Technical Analysis of Soleno Therapeutics Inc (SLNO)
Looking closely at Soleno Therapeutics Inc (NASDAQ: SLNO), its last 5-days average volume was 1.62 million, which is a jump from its year-to-date volume of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 50.96%. Additionally, its Average True Range was 2.79.
During the past 100 days, Soleno Therapeutics Inc’s (SLNO) raw stochastic average was set at 89.64%, which indicates a significant increase from 80.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.36% in the past 14 days, which was lower than the 58.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $49.20, while its 200-day Moving Average is $45.33. However, in the short run, Soleno Therapeutics Inc’s stock first resistance to watch stands at $56.16. Second resistance stands at $57.58. The third major resistance level sits at $60.23. If the price goes on to break the first support level at $52.09, it is likely to go to the next support level at $49.44. Now, if the price goes above the second support level, the third support stands at $48.02.
Soleno Therapeutics Inc (NASDAQ: SLNO) Key Stats
Market capitalization of the company is 2.13 billion based on 33,411K outstanding shares. Right now, sales total 0 K and income totals -38,990 K. The company made 0 K in profit during its latest quarter, and -21,850 K in sales during its previous quarter.
